Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. [electronic resource]
Producer: 20190204Description: e315-e322 p. digitalISSN:- 1938-0682
- Administration, Intravenous
- Administration, Oral
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Drug Administration Schedule
- Estramustine -- administration & dosage
- Humans
- Male
- Middle Aged
- Paclitaxel -- administration & dosage
- Prostate-Specific Antigen -- metabolism
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.